Blenoxane

Pleural Effusion, Malignant, Teratocarcinoma, Testicular Embryonal Carcinoma + 5 more

Treatment

10 FDA approvals

20 Active Studies for Blenoxane

What is Blenoxane

Bleomycin

The Generic name of this drug

Treatment Summary

Bleomycin is a type of antibiotic that is made up of two components, Bleomycin A2 and B2. It is derived from the <i>Streptomyces verticillus</i> bacteria and is used to treat certain types of cancer, particularly solid tumors. It works by inhibiting the metabolism of DNA. Bleomycin A2 is used as the primary structure for Bleomycin.

Bleomycin

is the brand name

image of different drug pills on a surface

Blenoxane Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Bleomycin

Bleomycin

2000

19

Approved as Treatment by the FDA

Bleomycin, also known as Bleomycin, is approved by the FDA for 10 uses such as Non-Hodgkin's Lymphoma (NHL) and Testicular Choriocarcinoma .

Non-Hodgkin's Lymphoma (NHL)

Helps manage Non-Hodgkin's Lymphoma (NHL)

Testicular Choriocarcinoma

Helps manage Testicular Choriocarcinoma

Palliative Treatment

Helps manage Palliative Treatment

Teratocarcinoma

Helps manage Teratocarcinoma

Pleural Effusion, Malignant

Helps manage Pleural Effusion, Malignant

Lymphoma, Hodgkins

Helps manage Lymphoma, Hodgkins

Pleural Effusion, Malignant

Helps manage Pleural Effusion, Malignant

Testicular Embryonal Carcinoma

Helps manage Testicular Embryonal Carcinoma

Non-Hodgkin's Lymphoma

Helps manage Non-Hodgkin's Lymphoma (NHL)

Hodgkin's Lymphoma

Helps manage Lymphoma, Hodgkins

Effectiveness

How Blenoxane Affects Patients

Bleomycin is an antibiotic that is used to fight tumors. It works by blocking the cell's ability to make DNA and RNA. Bleomycin has been found to stop the growth of B cells, T cells, and macrophages, which are all types of immune cells. It also affects how these cells present antigens and how they produce certain proteins. Bleomycin is unique among other antitumor drugs because it specifically targets cells during the G2 and M phases of the cell cycle.

How Blenoxane works in the body

Bleomycin works by inhibiting DNA, RNA, and protein synthesis. This process relies on the presence of oxygen and metal ions, which interact with bleomycin to form free radicals that damage DNA. This reaction can lead to cell death and stop cancer growth.

When to interrupt dosage

The suggested measure of Blenoxane is contingent upon the determined condition, for instance Testicular Embryonal Carcinoma, Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma. The amount of dosage depends on the delivery technique (e.g. Intramuscular; Intrapleural; Intravenous; Subcutaneous or Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous) as featured in the following table.

Condition

Dosage

Administration

Palliative Treatment

15.0 units, , 15.0 [USP'U], 30.0 [USP'U], 15000.0 [iU]

, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intravenous, Intra-arterial; Intramuscular; Intravenous

Non-Hodgkin's Lymphoma

15.0 units, , 15.0 [USP'U], 30.0 [USP'U], 15000.0 [iU]

, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intravenous, Intra-arterial; Intramuscular; Intravenous

Pleural Effusion, Malignant

15.0 units, , 15.0 [USP'U], 30.0 [USP'U], 15000.0 [iU]

, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intravenous, Intra-arterial; Intramuscular; Intravenous

Teratocarcinoma

15.0 units, , 15.0 [USP'U], 30.0 [USP'U], 15000.0 [iU]

, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intravenous, Intra-arterial; Intramuscular; Intravenous

Testicular Choriocarcinoma

15.0 units, , 15.0 [USP'U], 30.0 [USP'U], 15000.0 [iU]

, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intravenous, Intra-arterial; Intramuscular; Intravenous

Squamous Cell Carcinoma

15.0 units, , 15.0 [USP'U], 30.0 [USP'U], 15000.0 [iU]

, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intravenous, Intra-arterial; Intramuscular; Intravenous

Testicular Embryonal Carcinoma

15.0 units, , 15.0 [USP'U], 30.0 [USP'U], 15000.0 [iU]

, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intravenous, Intra-arterial; Intramuscular; Intravenous

Hodgkin's Lymphoma

15.0 units, , 15.0 [USP'U], 30.0 [USP'U], 15000.0 [iU]

, Intramuscular; Intravenous, Powder, for solution, Powder, for solution - Intramuscular; Intravenous, Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Powder, for solution - Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Intra-arterial; Intracavitary; Intramuscular; Intravenous; Subcutaneous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection - Intramuscular; Intrapleural; Intravenous; Subcutaneous, Injection, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intravenous, Intra-arterial; Intramuscular; Intravenous

Warnings

There are 20 known major drug interactions with Blenoxane.

Common Blenoxane Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Bleomycin is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Bleomycin is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abatacept

Major

The risk or severity of adverse effects can be increased when Bleomycin is combined with Abatacept.

Abetimus

Major

The risk or severity of adverse effects can be increased when Bleomycin is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Bleomycin is combined with Acteoside.

Blenoxane Toxicity & Overdose Risk

Too much exposure to bleomycin can result in fever, chills, nausea, vomiting, mental confusion, and difficulty breathing. The drug can also irritate the eyes, skin, and respiratory tract and make the skin darker or thicker. An allergic reaction is also possible.

image of a doctor in a lab doing drug, clinical research

Blenoxane Novel Uses: Which Conditions Have a Clinical Trial Featuring Blenoxane?

296 active trials are being conducted to investigate the potential of Blenoxane to target Teratocarcinoma, Testicular Choriocarcinoma and Malignant Pleural Effusions.

Condition

Clinical Trials

Trial Phases

Testicular Embryonal Carcinoma

0 Actively Recruiting

Teratocarcinoma

0 Actively Recruiting

Palliative Treatment

1 Actively Recruiting

Phase 3

Hodgkin's Lymphoma

63 Actively Recruiting

Phase 2, Phase 1, Phase 3, Not Applicable, Early Phase 1

Pleural Effusion, Malignant

3 Actively Recruiting

Phase 2, Phase 1

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Squamous Cell Carcinoma

32 Actively Recruiting

Phase 3, Phase 2, Not Applicable, Phase 1

Testicular Choriocarcinoma

0 Actively Recruiting

Patient Q&A Section about blenoxane

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is bleomycin used to treat?

"Bleomycin is an antibiotic that is only used in cancer chemotherapy. It slows or stops the growth of cancer cells in your body."

Answered by AI

How is Blenoxane administered?

"BLENOXANE should be injected intramuscularly, intravenously, subcutaneously, or intrapleurally with caution."

Answered by AI

What is the generic name for Blenoxane?

"Bleomycin is the name for the trade name drug Blenoxane. In some cases, health care professionals may use the trade name Blenoxane when referring to the generic drug name. Bleomycin is an anti-cancer ("antineoplastic" or "cytotoxic") chemotherapy drug."

Answered by AI

Clinical Trials for Blenoxane

Image of University of Nebraska Medical Center in Omaha, United States.

Exercise for Blood Cancer Survivors

18+
All Sexes
Omaha, NE

Older survivors of blood cancer are at a high risk of accelerated biological aging, which increases their risk of developing multiple aging-related conditions. Whereas physical exercise can improve overall health, older cancer survivors do not meet the recommended physical activity, highlighting the need to develop behavioral interventions to increase adherence. Several other knowledge gaps exist to implement exercise interventions in older survivors of blood cancer; the dose and duration of exercise necessary to slow biological aging in older blood cancer survivors remain unknown. To bridge these gaps in knowledge, we have designed a Phase 2 randomized control trial to test the effects of behavioral and exercise interventions on various outcomes.

Phase 2
Waitlist Available

University of Nebraska Medical Center

Image of Mayo Clinic in Florida in Jacksonville, United States.

In-Home Treatment for Cancer

18+
All Sexes
Jacksonville, FL

This phase II trial studies whether providing cancer treatment in the home is preferred over the traditional clinic setting and if it improves treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas. Typically, drug-related cancer care is provided at a medical center which causes patients to have to spend considerable time away from their family, friends, and familiar surroundings. This may add to the physical, emotional, social, and financial burden for patients and their families during this difficult time in their lives. The Cancer Connected Access and Remote Expertise (CARE) Beyond Walls (CCBW) program uses a specialized care team trained to provide cancer treatment in the patient's home setting. It is designed to support remote connection between the home health team and providers and Mayo clinic. This may be preferred over the traditional clinic setting which may improve treatment satisfaction in cancer patients living in the Florida Panhandle and surrounding areas.

Phase 2
Recruiting

Mayo Clinic in Florida

Roxana S. Dronca, MD

Have you considered Blenoxane clinical trials?

We made a collection of clinical trials featuring Blenoxane, we think they might fit your search criteria.
Go to Trials
Image of Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute in Cleveland, United States.

Vitamin D + PDT for Skin Cancer

18+
All Sexes
Cleveland, OH

This research study is for people who have been diagnosed with a nonmelanoma skin cancer (either basal cell carcinoma or squamous cell carcinoma) and are planning to receive either Mohs surgery or ED\&C (electrodessication \& curettage) as part of clinical care. The purpose of this study is to understand how photodynamic therapy (PDT) with or without Vitamin D can promote an immune response to skin cancer. For this study, participants will be randomized (randomly assigned) and asked to take Vitamin D or placebo for 6 days and come to the clinic for a single PDT treatment 1-14 days prior to their surgery. At this visit, photographs of participant's skin cancer will be taken, and participants will undergo PDT treatment. The study team will also take photos on the day of Mohs surgery or ED\&C. There will be up to two blood draws for research. If participants do not want to come in for a PDT treatment prior to their Mohs surgery or ED\&C, they will have the option to participate by only allowing the study team to collect data about their skin cancer and their tissue from Mohs surgery or ED\&C.

Waitlist Available
Dietary Supplement

Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute

Edward Maytin, MD, PhD

Image of Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center in Cleveland, United States.

Rituximab + Tafasitamab + NK Cells for Non-Hodgkin's Lymphoma

18+
All Sexes
Cleveland, OH

This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. The purpose of this study is to identify the recommended dose of allogeneic NK cells in combination with IL-2, Tafasitamab and Rituximab for the treatment of relapsed or refractory B-cell non-Hodgkin's lymphoma. NK cells are an investigational (experimental) treatment which means they are not approved by the Food and Drug Administration (FDA). NK cells are a type of lymphocyte that's part of the body's natural immune system, and they can kill cancer cells by creating pores in the cancer cell membranes and inducing apoptosis (programmed cell death). Participants in this study will receive lymphodepleting chemotherapy, as well as Allogeneic NK cells, Tafasitamab and Interleukin-2 (IL-2) by an intravenous (IV) infusion. Participants are expected to complete one cycle, and they may be eligible to complete a second cycle of the same regiment if they have stable disease, partial or complete remission at the end of the first cycle. Participants will be in this study for about 12 months.

Phase 1
Waitlist Available

Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center (+1 Sites)

Paolo Caimi, MD

Incyte Corporation

Have you considered Blenoxane clinical trials?

We made a collection of clinical trials featuring Blenoxane, we think they might fit your search criteria.
Go to Trials
Image of St. Jude Children's Research Hospital in Memphis, United States.

High Intensity Interval Training for Hodgkin's Lymphoma Survivors

10 - 25
All Sexes
Memphis, TN

This pilot study evaluates the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Preliminary efficacy of the HIIT intervention for improved cardiorespiratory fitness, body composition, physical function, autonomic response to exercise, peripheral neuropathy, biological aging markers, and physical activity will also be evaluated. Primary Objective: To determine the feasibility of a 12-week high intensity interval training (HIIT) program in survivors of childhood, adolescent, and young adult Hodgkin lymphoma within 24 months of completing treatment. Feasibility will be assessed by: * Participation Rate: Number of eligible survivors approached who enroll. * Completion Rate: Number of scheduled HIIT sessions attended and number of enrolled participants who complete post-intervention testing.

Waitlist Available
Has No Placebo

St. Jude Children's Research Hospital

Amy Berkman, MD

Image of AHN West Penn Hospital in Pittsburgh, United States.

Fast TILs + Interleukin-2 for Mesothelioma

18 - 79
All Sexes
Pittsburgh, PA

This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma. The ACT product is created at AHN West Penn using the participant's pleural infiltrating T-cells (PIT). It is administered through a pleural catheter along with the drug Interleukin-2 (IL-2). Based on previous research it is believed that it may help fight the tumor and relieve symptoms. As a participant, their pleural fluid will be collected and the PIT cells will be isolated and expanded in the lab to create the ACT product. Before receiving the ACT product through their pleural catheter, they will undergo outpatient lymphodepleting chemotherapy. LDC is a standard procedure for many approved immunotherapy treatments Following the infusion, they'll receive IL-2 through the catheter for two days to stimulate the expanded PIT cells. The active treatment phase lasts about three weeks, with follow-up visits over five years at AHN West Penn Hospital, potentially requiring a hospital stay of up to six days. Blood samples will be taken to monitor their response. As this is a first-in-human study, treatment carries an unknown risk up to and including death from toxicity. However, the risks of similar immunotherapy treatments are well documented.

Phase 1
Recruiting

AHN West Penn Hospital

David Bartlett, MD

Miltenyi Biotec, Inc.

Have you considered Blenoxane clinical trials?

We made a collection of clinical trials featuring Blenoxane, we think they might fit your search criteria.
Go to Trials